Cisplatin in recurrent pediatric brain tumors A pog phase II study a pediatric oncology group study
- 1 October 1985
- Vol. 56 (7) , 1497-1501
- https://doi.org/10.1002/1097-0142(19851001)56:7<1497::aid-cncr2820560703>3.0.co;2-7
Abstract
Forty-six evaluable pediatric patients with primary recurrent brain tumors resistant to standard therapy were treated with cisplatin, 60 mg/m2/day, X2 days every 3 to 4 weeks, to study the efficacy and toxicity of this drug. Complete and partial responses, documented by computed tomography (CT) scan, were demonstrated in 4 of 10 patients with medulloblastoma and 3 of 15 patients with ependymoma. No activity was documented in astrocytic tumors. Dose limiting major toxicities were renal and auditory. It is recommended that the new analogues of cisplatin with less toxicity be studied in these tumors.This publication has 7 references indexed in Scilit:
- HUMAN CENTRAL NERVOUS-SYSTEM DISTRIBUTION OF CIS-DIAMMINEDICHLOROPLATINUM AND USE AS A RADIOSENSITIZER IN MALIGNANT BRAIN-TUMORS1982
- CISPLATIN THERAPY IN RECURRENT CHILDHOOD BRAIN-TUMORS1982
- PHASE II EVALUATION OF CISPLATIN IN CHILDREN WITH NEUROBLASTOMA AND OTHER MALIGNANT SOLID TUMORSPublished by Elsevier ,1980
- Cis‐diamminedichloroplatinum (NSC‐119875) in childhood malignancies: A southwest oncology group studyMedical and Pediatric Oncology, 1978
- CLINICAL RESPONSE AND TOXICITY WITH CIS-DICHLORODIAMMINEPLATINUM(II) IN CHILDREN1977
- Diaminodichloroplatinum: A phase I study showing responses in testicular and other tumorsCancer, 1974